Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Fineline Cube Jul 28, 2026
Company Drug

Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jul 28, 2026
Company Drug

Everest Medicines Commences Commercial Sales of Nefecon in China Post-Launch

Fineline Cube May 15, 2024

Everest Medicines (HKG: 1952), a leading pharmaceutical company based in China, has announced the official...

Company Deals

Elite (Suzhou) Analytical Instruments Boosts Liquid Chromatography Push with Series A+ Round

Fineline Cube May 15, 2024

China-based Elite (Suzhou) Analytical Instruments Co., Ltd, a premier manufacturer of liquid chromatography devices in...

Company Policy / Regulatory

US Readies Hefty Tariffs on Chinese Medical Equipment and Other Imports

Fineline Cube May 15, 2024

The US Office of the Trade Representative (USTR) has announced a series of stringent new...

Company

Genmab CEO Cites China’s Biotech as a ‘Mind-Boggling’ Source of Innovation

Fineline Cube May 15, 2024

Jan van de Winkel, CEO of Denmark-based biotech Genmab (NASDAQ: GMAB), has expressed optimism about...

Company Drug

Fosun Pharmaceutical Advances Lasofocine Clinical Trials for Breast Cancer after NMPA Nod

Fineline Cube May 15, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...

Company Drug

Zai Lab Advances Vygart Hytrulo for CIDP with sBLA Filing in China

Fineline Cube May 15, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, has announced...

Company Drug

Jiangsu Hengrui’s SHR-2173 Gets Green Light for Clinical Trial in IgA Nephropathy

Fineline Cube May 15, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Drug

ViiV Healthcare’s HIV-PreP Therapy Approved by China’s NMPA, Offers Alternative to Daily Medication

Fineline Cube May 15, 2024

GlaxoSmithKline’s (GSK; NYSE: GSK) subsidiary, ViiV Healthcare, has announced that it has received marketing approvals...

Company Drug

Tonghua Dongbao Pharmaceuticals Begins Clinical Trial for Xultophy Biosimilar

Fineline Cube May 15, 2024

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the dosing of the...

Policy / Regulatory

China Launches Nationwide Unannounced Inspections of Medical Insurance Funds

Fineline Cube May 15, 2024

An inaugural meeting for the first batch of unannounced medical insurance fund inspections was conducted...

Company Drug

Novo Nordisk’s Wegovy Shows Durable Weight Loss and Heart Health in Extended Trials

Fineline Cube May 15, 2024

At the 31st European Congress on Obesity (ECO), Denmark’s pharmaceutical giant Novo Nordisk (CPH: NOVO-B)...

Company Drug

RemeGen’s Telitacicept Achieves Full Enrollment in Phase III Primary Sjogren’s Syndrome Trial

Fineline Cube May 15, 2024

China-based pharmaceutical company RemeGen (HKG: 9995) has announced the completion of patient enrollment in a...

Company Drug

Bayer’s Q1 2024 Report Shows Slight Dip in Sales Amid Pharmaceutical Unit’s Growth

Fineline Cube May 15, 2024

Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2024,...

Company Drug

Novo Nordisk’s Bispecific Antibody Mim8 Achieves Milestone in Haemophilia A Trial

Fineline Cube May 15, 2024

Novo Nordisk (CPH: NOVO-B), a pharmaceutical company based in Denmark, has announced that its bispecific...

Company Drug

Novo Nordisk’s Mim8 for Haemophilia A Exceeds Endpoints in Late-Stage Trial

Fineline Cube May 15, 2024

Denmark-based healthcare company Novo Nordisk (CPH: NOVO-B) has announced positive results from a late-stage trial...

Company Drug

Roche and Genprex Initiate Phase I Trial Combining Tecentriq and Reqorsa for ES-SCLC

Fineline Cube May 15, 2024

Switzerland-based Roche (SWX: ROG) is advancing the evaluation of its anti-PD-L1 drug, Tecentriq (atezolizumab), in...

Company Drug

BeiGene’s Brukinsa Secures Conditional Approval in China for R/R Follicular Lymphoma

Fineline Cube May 14, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company based in China,...

Company Deals

AbbVie and Gilgamesh Pharmaceuticals Join Forces to Develop Psychiatric Disorder Therapies

Fineline Cube May 14, 2024

AbbVie (NYSE: ABBV) has announced a partnership with US-based Gilgamesh Pharmaceuticals to develop a portfolio...

Company Drug

MSD Discontinues Vibostolimab and Keytruda Combo Trial in High-Risk Melanoma

Fineline Cube May 14, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced its decision to cease development of...

Policy / Regulatory

NMPA Seeks Public Comment on Draft Proposal for Drug Re-Registration Procedures

Fineline Cube May 14, 2024

The National Medical Products Administration (NMPA) of China has released a draft proposal for the...

Posts pagination

1 … 395 396 397 … 700

Recent updates

  • HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases
  • Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals
  • China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio
  • Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy
  • CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Company

Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals

Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Company Medical Device

Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.